Drug Profile
Doxorubicin encapsulated nanoparticles - NanoVector
Alternative Names: NVI-9010Latest Information Update: 14 Sep 2023
Price :
$50
*
At a glance
- Originator NanoVector
- Class Anthracyclines; Antineoplastics; Cytostatic antibiotics; Doxorubicins; Small molecules
- Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Malignant melanoma; Ovarian cancer
Most Recent Events
- 14 Sep 2023 Discontinued - Preclinical for Malignant melanoma in USA (unspecified route), prior to September 2023
- 14 Sep 2023 Discontinued - Preclinical for Ovarian cancer in USA (unspecified route), prior to September 2023
- 28 Sep 2020 No recent reports of development identified for preclinical development in Malignant-melanoma in USA